The Cooper Companies, Inc. (NASDAQ:COO) Shares Sold by Mount Yale Investment Advisors LLC

Mount Yale Investment Advisors LLC lessened its stake in The Cooper Companies, Inc. (NASDAQ:COO) by 4.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,411 shares of the medical device company’s stock after selling 307 shares during the period. Mount Yale Investment Advisors LLC’s holdings in Cooper Companies were worth $647,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Benjamin F. Edwards & Company Inc. boosted its position in shares of Cooper Companies by 248.6% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 244 shares of the medical device company’s stock valued at $25,000 after purchasing an additional 174 shares during the period. Innealta Capital LLC purchased a new position in shares of Cooper Companies during the second quarter worth approximately $25,000. Covestor Ltd grew its position in shares of Cooper Companies by 305.9% during the first quarter. Covestor Ltd now owns 276 shares of the medical device company’s stock worth $28,000 after acquiring an additional 208 shares during the last quarter. Crewe Advisors LLC increased its holdings in shares of Cooper Companies by 286.4% in the 2nd quarter. Crewe Advisors LLC now owns 340 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 252 shares during the period. Finally, Tortoise Investment Management LLC raised its position in Cooper Companies by 75.4% in the 2nd quarter. Tortoise Investment Management LLC now owns 393 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 169 shares during the last quarter. Hedge funds and other institutional investors own 24.39% of the company’s stock.

Cooper Companies Stock Performance

NASDAQ:COO opened at $109.81 on Tuesday. The firm’s fifty day simple moving average is $98.35 and its 200-day simple moving average is $95.51. The company has a quick ratio of 1.18, a current ratio of 1.99 and a debt-to-equity ratio of 0.33. The stock has a market cap of $21.87 billion, a PE ratio of 64.59, a price-to-earnings-growth ratio of 2.60 and a beta of 0.98. The Cooper Companies, Inc. has a fifty-two week low of $75.93 and a fifty-two week high of $112.38.

Cooper Companies (NASDAQ:COO) last issued its earnings results on Wednesday, August 28th. The medical device company reported $0.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.91 by $0.05. Cooper Companies had a net margin of 9.45% and a return on equity of 9.08%. The company had revenue of $1 billion during the quarter, compared to analysts’ expectations of $997.30 million. During the same period last year, the company posted $0.84 earnings per share. The firm’s quarterly revenue was up 7.8% compared to the same quarter last year. Analysts expect that The Cooper Companies, Inc. will post 3.66 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Albert G. White III sold 114,992 shares of the firm’s stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $110.53, for a total value of $12,710,065.76. Following the completion of the transaction, the chief executive officer now owns 165,273 shares in the company, valued at $18,267,624.69. The sale was disclosed in a document filed with the SEC, which is available at this link. In other Cooper Companies news, CEO Albert G. White III sold 114,992 shares of the company’s stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $110.53, for a total value of $12,710,065.76. Following the sale, the chief executive officer now owns 165,273 shares of the company’s stock, valued at $18,267,624.69. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Agostino Ricupati sold 1,601 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $108.03, for a total transaction of $172,956.03. Following the transaction, the chief accounting officer now directly owns 4,818 shares of the company’s stock, valued at $520,488.54. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 256,373 shares of company stock worth $27,637,427. 2.00% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have issued reports on COO. Needham & Company LLC reissued a “hold” rating on shares of Cooper Companies in a research report on Thursday, August 29th. Piper Sandler boosted their price target on Cooper Companies from $115.00 to $120.00 and gave the company an “overweight” rating in a research report on Thursday, August 29th. Jefferies Financial Group raised Cooper Companies from a “hold” rating to a “buy” rating and increased their price objective for the stock from $107.00 to $115.00 in a research report on Tuesday, July 16th. Robert W. Baird boosted their target price on Cooper Companies from $118.00 to $125.00 and gave the company an “outperform” rating in a report on Thursday, August 29th. Finally, Morgan Stanley upped their price target on Cooper Companies from $95.00 to $104.00 and gave the stock an “equal weight” rating in a research note on Tuesday, September 10th. Four equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, Cooper Companies currently has an average rating of “Moderate Buy” and an average price target of $115.00.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.